The discovery of this functional interaction provided a molecular explanation as to why BTK inhibition is exquisitely toxic to tumours carrying concurrent MYD88 and CD79B mutations, which are only observed in MCD-DLBCL, while MYD88L265P-only mutant DLBCLs are insensitive to this treatment. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.